Clinical Trial Update: Safety, Tolerability, and Effectiveness of CGP77116 in Patients With Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

The National Institute of Neurological Disorders and Stroke completed a Phase 2 trial evaluating CGP77116 in multiple sclerosis, reporting on safety, tolerabili…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• CGP77116

Snippet

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED